ArticleBMC microbiology2019
Cross-resistance of the pathogenic fungus Alternaria alternata to fungicides with different modes of action.
Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- Occurrence, toxicity, dietary exposure, and management of Alternaria mycotoxins in food and feed: A systematic literature review.Comprehensive reviews in food science and food safety · 2025Pooled it
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- Fungal disease management in cotton using plant protection products: An Australian perspective.Pest management science · 2026Review
- Untargeted LC-HRMS Metabolomics for the Detection of Alternaria-Infected Apples Under Retail and Storage Conditions.Toxins · 2026Article
- Historical comparative genomics to track the evolution of fungal pathogens: a proof of concept.BMC genomics · 2026Article
- Nanotechnology-driven strategies to overcome azole resistance inFrontiers in plant science · 2026Review
- Article
- Development of Procymidone and Difenoconazole Resistance inPlants (Basel, Switzerland) · 2025Article
- The Antifungal Activity and Mechanism of Dehydroabietic Acid AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Novel Regulators and Their Epistatic Networks in Arabidopsis' Defence Responses to Alternaria alternata Infection.Molecular plant pathology · 2025Article
- Integrative transcriptome and WGCNA analysis reveal key genes mainly in response toFrontiers in plant science · 2025Article
- Bioassay-Guided Fractionation Networking for Discovery of Biofungicides from CultivatedInternational journal of molecular sciences · 2024Article
- Investigation of Antimicrobial Compounds Produced by Endolichenic Fungi in Different Culture Media.The plant pathology journal · 2024Article
- Efficacy ofAntibiotics (Basel, Switzerland) · 2024Article
- What are the 100 most cited fungal genera?Studies in mycology · 2024Article
- In Vitro Evaluation of Azoxystrobin, Boscalid, Fentin-Hydroxide, Propiconazole, Pyraclostrobin Fungicides againstMicroorganisms · 2023Article
- Antifungal Activity of Green and Chemically Synthesized ZnO Nanoparticles against Alternaria citri, the Causal Agent Citrus Black Rot.The plant pathology journal · 2023Article
- Hydroxylated Cinnamates Enhance Tomato Resilience toPlants (Basel, Switzerland) · 2023Article
- Triazoles and Strobilurin Mixture Affects Soil Microbial Community and Incidences of Wheat Diseases.Plants (Basel, Switzerland) · 2023Article
- Seed dressing with M451 promotes seedling growth in wheat and reduces root phytopathogenic fungi without affecting endophytes.Frontiers in plant science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCross-resistance, a phenomenon that a pathogen resists to one antimicrobial compound also resists to one or several other compounds, is one of major threats to human health and sustainable food production. It usually occurs among antimicrobial compounds sharing the mode of action. In this study, we determined the sensitivity profiles of Alternaria alternata, a fungal pathogen which can cause diseases in many crops to two fungicides (mancozeb and difenoconazole) with different mode of action using a large number of isolates (234) collected from seven potato fields across China.
resultsWe found that pathogens could also develop cross resistance to fungicides with different modes of action as indicated by a strong positive correlation between mancozeb and difenoconazole tolerances to A. alternata. We also found a positive association between mancozeb tolerance and aggressiveness of A. alternata, suggesting no fitness penalty of developing mancozeb resistance in the pathogen and hypothesize that mechanisms such as antimicrobial compound efflux and detoxification that limit intercellular accumulation of natural/synthetic chemicals in pathogens might account for the cross-resistance and the positive association between pathogen aggressiveness and mancozeb tolerance.
conclusionsThe detection of cross-resistance among different classes of fungicides suggests that the mode of action alone may not be an adequate sole criterion to determine what components to use in the mixture and/or rotation of fungicides in agricultural and medical sects. Similarly, the observation of a positive association between the pathogen's aggressiveness and tolerance to mancozeb suggests that intensive application of site non-specific fungicides might simultaneously lead to reduced fungicide resistance and enhanced ability to cause diseases in pathogen populations, thereby posing a greater threat to agricultural production and human health. In this case, the use of evolutionary principles in closely monitoring populations and the use of appropriate fungicide applications are important for effective use of the fungicides and durable infectious disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.